Entresto Label: Strong Efficacy, Complex Dosing
PARADIGM-HF study shows 20% reduced risk of CV death and heart failure hospitalization compared to ACE inhibitor enalapril.
PARADIGM-HF study shows 20% reduced risk of CV death and heart failure hospitalization compared to ACE inhibitor enalapril.